search

The Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) and others

in The Journal of Infectious Diseases

The Journal of Infectious Diseases, Volume 207, Issue 5, 1 March 2013, Pages 759–767, https://doi.org/10.1093/infdis/jis752

Published: 07 December 2012

Supplementary data

Journal Article

Association of Soluble CD14 and Inflammatory Biomarkers With HIV-2 Disease Progression Get access

PDF

Rodolphe Thiébaut and others

in Clinical Infectious Diseases

Clinical Infectious Diseases, Volume 55, Issue 10, 15 November 2012, Pages 1417–1425, https://doi.org/10.1093/cid/cis708

Published: 20 August 2012

Journal Article

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm³ compared with the general population: evidence from a large European observational cohort collaboration Get access

PDF

The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord and others

in International Journal of Epidemiology

International Journal of Epidemiology, Volume 41, Issue 2, April 2012, Pages 433–445, https://doi.org/10.1093/ije/dyr164

Published: 28 November 2011

Supplementary data

Journal Article

Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2–Infected Patients: The ACHI_EV_2E Collaboration Study Group Get access

PDF

Antoine Benard and others

in Clinical Infectious Diseases

Clinical Infectious Diseases, Volume 52, Issue 10, 15 May 2011, Pages 1257–1266, https://doi.org/10.1093/cid/cir123

Published: 15 May 2011

2 3

Modify your search

Availability

NARROW

Format

Subject

Type

Journal

Publication date

Developing evidence-based, values-driven skills: WHO-ISPED European public health leadership course 2023

Are Trends in Dementia Incidence Associated With Compression in Morbidity? Evidence From The Framingham Heart Study

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)

Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery Get access

The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era Get access

Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts Get access

Predictors of CD4⁺ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes Get access

Association of Soluble CD14 and Inflammatory Biomarkers With HIV-2 Disease Progression Get access

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm³ compared with the general population: evidence from a large European observational cohort collaboration Get access

Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2–Infected Patients: The ACHI_EV_2E Collaboration Study Group Get access

Modify your search

Publication date

Developing evidence-based, values-driven skills: WHO-ISPED European public health leadership course 2023 Open Access

Are Trends in Dementia Incidence Associated With Compression in Morbidity? Evidence From The Framingham Heart Study Free

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2) Open Access

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM) Free

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study Free

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord Free

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia Free

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe Free

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study Open Access

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen Free

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART Free

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial Free

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial) Free

This Feature Is Available To Subscribers Only

Developing evidence-based, values-driven skills: WHO-ISPED European public health leadership course 2023

Are Trends in Dementia Incidence Associated With Compression in Morbidity? Evidence From The Framingham Heart Study

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)